Medicare Enrolled

Dr. Shrinivas Diggikar, M.D.

Medical Oncology · Arlington, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
515 W MAYFIELD RD, Arlington, TX 76014
8174676092
In practice since 2006 (19 years)
NPI: 1942248901 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Diggikar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Diggikar? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Diggikar

Dr. Shrinivas Diggikar is a medical oncology in Arlington, TX, with 19 years in practice. Based on federal Medicare data, Dr. Diggikar performed 27,172 Medicare services across 1,519 unique beneficiaries.

Between the years covered by Open Payments, Dr. Diggikar received a total of $5,669 from 20 pharmaceutical and/or device companies across 32 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Diggikar is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 32% volume in TX$ $5,669 industry payments

Medicare Practice Summary

Medicare Utilization ↗
27,172
Medicare services
Top 32% in TX for medical oncology
1,519
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,430 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Oxaliplatin chemotherapy injection8,200$0$33
Contrast dye for imaging (iodine-based)5,029$0$3
Iron sucrose injection (Venofer)4,700$0$2
Anti-nausea injection (fosaprepitant)4,350$0$5
Dexamethasone injection (steroid)684$0$1
Blood draw (venipuncture)644$8$20
Complete blood count (CBC) with differential550$8$36
Injection, leucovorin calcium, per 50 mg424$3$25
Comprehensive metabolic blood panel323$10$64
Office visit, established patient (20-29 min)321$63$250
Anti-nausea injection (Aloxi/palonosetron)290$1$114
Injection, fluorouracil, 500 mg250$2$13
Injection of additional new drug or substance into vein145$12$108
Lactate dehydrogenase (enzyme) level112$6$31
Microscopic examination for white blood cells with manual cell count80$4$22
Complete blood count (CBC), automated80$6$34
Administration of chemotherapy into vein, 1 hour or less78$101$707
Hospital follow-up visit, moderate complexity77$60$247
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less70$23$157
Office visit, established patient (30-39 min)69$100$368
Drug injection, under skin or into muscle60$10$96
Ferritin level test (iron stores)59$13$60
Iron level test57$6$27
Iron binding capacity test57$9$35
Ct scan of chest with contrast49$47$821
CT scan of abdomen and pelvis with contrast47$180$1,067
Administration of chemotherapy into vein, each additional hour44$22$161
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion33$16$94
Magnesium level test30$7$29
Administration of additional new drug or substance into vein, 1 hour or less30$51$344
Initial hospital admission, high complexity30$125$694
Hospital follow-up visit, high complexity30$92$357
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less29$47$313
Irrigation of implanted venous access drug delivery device27$18$114
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l24$133$500
Nuclear medicine study from skull base to mid-thigh with ct scan23$1,156$4,802
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries22$91$657
New patient office visit, complex (60-74 min)19$154$709
New patient office visit (45-59 min)14$112$565
Initial hospital admission, moderate complexity12$93$470
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.6% high complexity
89.7% medium
9.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$5,669
Total received (2018-2024)
Avg $810/year across 7 years
Top 45% in TX for medical oncology
20
Companies
32
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$5,262 (92.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$336 (5.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$71 (1.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,475
2023
$76
2022
$44
2021
$24
2020
$27
2019
$3,932
2018
$92

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Celgene Corporation
$2,424
Janssen Biotech, Inc.
$1,459
AstraZeneca Pharmaceuticals LP
$1,430
Eisai Inc.
$37
PharmaEssentia USA Corporation
$35
Amgen Inc.
$28
Acrotech Biopharma LLC
$24
Merck Sharp & Dohme LLC
$23
Seattle Genetics, Inc.
$23
Genentech USA, Inc.
$21
Taiho Oncology, Inc.
$20
Astellas Pharma US Inc
$20
Novartis Pharmaceuticals Corporation
$19
EISAI INC.
$19
Kite Pharma, Inc.
$17
Blueprint Medicines Corporation
$16
Merck Sharp & Dohme Corporation
$16
GlaxoSmithKline, LLC.
$14
Seagen Inc.
$13
Gilead Sciences, Inc.
$12
Top 3 companies account for 93.7% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · BELEODAQ · BESREMI · CRESTOR · DARZALEX · IMFINZI · KEYTRUDA · Kyprolis · Lenvima · Lonsurf · OJJAARA · PLUVICTO · Perjeta · Revlimid · XOSPATA · Yescarta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (93%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.

Equivalent to $21 per 100 Medicare services performed
Looking for a medical oncology in Arlington?
Compare medical oncologys in the Arlington area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
87
Per 100K population
4.1
County median income
$81,905
Nearest hospital
MEDICAL CITY ARLINGTON
2.9 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Diggikar is a mixed practice specialist, with moderate Medicare volume, and consulting-driven industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Diggikar experienced with oxaliplatin chemotherapy injection?
Based on Medicare claims data, Dr. Diggikar performed 8,200 oxaliplatin chemotherapy injection services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Diggikar receive payments from pharmaceutical companies?
Yes. Dr. Diggikar received a total of $5,669 from 20 companies across 32 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Diggikar's costs compare to other medical oncologys in Arlington?
Dr. Diggikar's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Diggikar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →